CurrentCignaPolicy N/A

Hyperhidrosis - Qbrexza Prior Authorization Policy

This policy governs prior authorization requirements and medical necessity criteria for coverage of Qbrexza (glycopyrronium cloth 2.4%) for treatment of primary axillary hyperhidrosis in Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyHyperhidrosis - Qbrexza Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateMay 14, 2025

Key ActionObtain prior authorization and document age ≥9, impact on activities of daily living, exclusion of secondary causes, and prior trial or intolerance of a prescription aluminum chloride antiperspirant.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥9minimum patient age for approval

1 yrapproval duration if criteria met

4 wksantiperspirant trial

axillaesite of indicated use

Sofdra concurrentexplicitly not covered

Coverage Criteria for Qbrexza (glycopyrronium cloth 2.4%)

Initial therapy — FDA-approved indication

Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

FDA-Approved Indication - Primary Axillary Hyperhidrosis

D - prior antiperspirant trial or intolerance: i. Patient has tried one prescription aluminum chloride-containing topical antiperspirant for at least 4 weeks and experienced inadequate efficacy; OR ii. According to the prescriber, the patient has experienced significant intolerance with an aluminum-containing topical antiperspirant.4 weeks
Examples include aluminum chloride 20% topical solution (Drysol, generics).

Qbrexza (glycopyrronium cloth 2.4%) is approved only for primary axillary hyperhidrosis. It is not intended for application to areas other than the axillae; use for hyperhidrosis at non-axillary sites is considered not medically necessary.

Concurrent therapy with Sofdra (sofpironium 12.45% topical gel) is not covered. The safety and efficacy of using Qbrexza together with Sofdra have not been established, and requests for concurrent use will be denied.

Policy Summary

PayerCigna

PolicyHyperhidrosis - Qbrexza Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateMay 14, 2025

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Requirements and Authorization Workflow

Prior Authorization

Prior Authorization Recommended

Prior authorization recommended. Approvals provided for 1 year when criteria are met.

Qbrexza (glycopyrronium cloth 2.4%) — prior authorization recommended
Approval duration: 1 year when medical necessity criteria are satisfied

Step Therapy

Step Therapy Requirement

Trial of a prescription aluminum chloride–containing topical antiperspirant for ≥4 weeks is required unless the prescriber documents significant intolerance.

Example: aluminum chloride 20% topical solution (Drysol, generics)
Step-therapy requirement may be bypassed if significant intolerance to aluminum-containing topical antiperspirant is documented by the prescriber

Documentation Required

Required Clinical Documentation

Requests must include documentation of patient age, functional impact, exclusion of secondary causes, and prior topical therapy or intolerance.

Document age ≥9 years
Document that hyperhidrosis significantly interferes with age-appropriate activities of daily living (ADLs)
Document that secondary causes of hyperhidrosis have been excluded
Document trial of a prescription aluminum chloride–containing topical antiperspirant for ≥4 weeks with inadequate efficacy, or document significant intolerance to such therapy

Denial Risk

Conditions Leading to Denial

Use for non-axillary hyperhidrosis or concurrent use with Sofdra will be considered not medically necessary and denied.

Not covered for hyperhidrosis other than primary axillary (Qbrexza is not intended for non-axillary application)
Not covered for concurrent use with Sofdra (sofpironium 12.45% topical gel)

Denial Risk

Missing Required Medical Necessity Criteria

Requests that do not include the required medical necessity documentation will be denied or returned for additional information.

Missing documentation of age (≥9 years)
Missing documentation that hyperhidrosis significantly impacts ADLs
Missing documentation that secondary causes have been excluded
Missing documentation of step-therapy trial (≥4 weeks) of a prescription aluminum chloride–containing topical antiperspirant or documentation of intolerance

Key Definitions

Primary axillary hyperhidrosis — definition and relation to indication

DefinitionExcessive sweating localized to the underarm (axillary) region not caused by a secondary medical condition; indication for Qbrexza (glycopyrronium cloth 2.4%) in patients ≥ 9 years.

Anatomic site of useApplied to clean, dry skin of the underarm (axillae) only; not intended for other body areas.

Age criterionIndicated for patients aged ≥ 9 years.

Dosing form relevant to indicationSingle cloth applied once every 24 hours to both underarms (1 cloth per day).

Prescription aluminum chloride–containing topical antiperspirant (examples)

Definition / examplesPrescription aluminum chloride–containing topical antiperspirants (commonly aluminum chloride hexahydrate 20% topical solution, e.g., Drysol or generics).

Place in treatment algorithmConsidered first-line therapy for primary axillary hyperhidrosis before second-line options like Qbrexza, Sofdra, or botulinum toxin A injections.

Minimum trial requirementPolicy requires a trial of one prescription aluminum chloride–containing topical antiperspirant for at least 4 weeks with inadequate efficacy, or documented significant intolerance, prior to Qbrexza approval.

OpenPayer

Hyperhidrosis - Qbrexza Prior Authorization Policy

Coverage Criteria for Qbrexza (glycopyrronium cloth 2.4%)

Provider Requirements and Authorization Workflow

Key Definitions

Background